COMP <GO>
VTRS vs ROIV // RETURN ON INVESTED CAPITAL (ROIC)
Viatris Inc. (NASDAQ) VS. Roivant Sciences Ltd. (NASDAQ) • 15-METRIC TALLY: VTRS 8
— ROIV 3
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: VTRS
LAST: $18.67 (-1.92%) • MKT CAP: $21.86B
roic
-8.10%
LAST: $35.89 (-2.76%) • MKT CAP: $26.66B
roic
-14.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VTRS VS. ROIV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VTRS | ROIV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -8.10% | -14.00% | +5.90 | VTRS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 8.78% | -2.80% | +11.58 | VTRS | /fcf-yield <GO> |
| Operating Margin | -18.70% | -60.00% | +41.30 | VTRS | /operating-margins <GO> |
| Net Profit Margin | -14.60% | -60.00% | +45.40 | VTRS | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | -65.00% | +62.00 | VTRS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.81 | 26.00 | -25.19 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 3/9 | +3.00 | VTRS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.5 | 53.3 | +9.20 | VTRS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.00 | +0.15 | VTRS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 28.0x | +5.00 | ROIV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $21.86B | $26.66B | -$4.80B | ROIV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VTRS REV | ROIV REV | VTRS GROSS % | ROIV GROSS % | VTRS FCF | ROIV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.25B | $8.3M | 35.2% | — | $1.94B | -$758.6M |
| FY 2024 | $14.69B | $29.1M | 38.3% | — | $1.98B | -$844.0M |
| FY 2023 | $15.39B | $32.7M | — | — | $2.21B | -$766.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VTRS // BETA 1.15
ROIV // BETA 1.00